Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610767 | 0.87 | NR1I2 (0.44) | NR1I2POLBTSHRSMN1; SMN2RORC | |
| SCHEMBL3613865 | 0.86 | NR1I2 (0.43) | NR1I2POLBTSHRSMN1; SMN2RORC | |
| SCHEMBL3607627 | 0.84 | ACE (0.47) | NR1I2LMNAPOLBTSHRSMN1; SMN2 | |
| SCHEMBL3607354 | 0.83 | ACE (0.46) | NR1I2LMNAPOLBTSHRSMN1; SMN2 | |
| SCHEMBL3611794 | 0.83 | NR1I2 (0.41) | NR1I2LMNAPOLBTSHRSMN1; SMN2 | |
| SCHEMBL3600789 | 0.80 | RORC (0.43) | NR1I2RORCMTNR1BTP53 | |
| SCHEMBL3612619 | 0.79 | GHSR (0.51) | — | |
| SCHEMBL3611673 | 0.76 | RORC (0.36) | NR1I2POLBTSHRSMN1; SMN2RORC | |
| SCHEMBL3616055 | 0.76 | RORC (0.38) | RORCMTNR1B | |
| Hydrochloric Acid SCHEMBL3604710 | 0.74 | RORC (0.36) | RORCMTNR1BMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | NR1I2 634/4885LMNA 4557/4885POLB 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.